A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

OBJECTIVE: This 24‐week, phase IIb, double‐blind study was undertaken to evaluate the efficacy and safety of mavrilimumab (a monoclonal antibody to granulocyte–macrophage colony‐stimulating factor receptor α) and golimumab (a monoclonal antibody to tumor necrosis factor [anti‐TNF]) in patients with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Weinblatt, Michael E., McInnes, Iain B., Kremer, Joel M., Miranda, Pedro, Vencovsky, Jiri, Guo, Xiang, White, Wendy I., Ryan, Patricia C., Godwood, Alex, Albulescu, Marius, Close, David, Burmester, Gerd R.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5767745/
https://ncbi.nlm.nih.gov/pubmed/28941039
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40323
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados